In the randomized, placebo-controlled, double-blind phase 2 SORMAIN trial, 83 patients with FLT3-ITD-mutated AML in CR (71% in CR1, 28% outside CR1) following HCT were assigned to receive either sorafenib (maximum dose of 400 mg twice daily [BID]) or placebo for two years [23]. This evidence concerns the gene FLT3 and acute myeloid leukemia.